|
1
|
Miettinen M and Lasota J: Gastrointestinal
stromal tumors: Review on morphology, molecular pathology,
prognosis, and differential diagnosis. Arch Pathol Lab Med.
130:1466–1478. 2006.PubMed/NCBI
|
|
2
|
Reith JD, Goldblum JR, Lyles RH and Weiss
SW: Extra-gastrointestinal (soft tissue) stromal tumors: An
analysis of 48 cases with emphasis on histologic predictors of
outcome. Mod Pathol. 13:577–585. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tran T, Davila JA and El-Serag HB: The
epidemiology of malignant gastrointestinal stromal tumors: An
analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol.
100:162–168. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hirota S, Isozaki K, Moriyama Y, Hashimoto
K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M,
et al: Gain-of-function mutations of c-kit in human
gastrointestinal stromal tumors. Science. 279:577–580. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Heinrich MC, Corless CL, Duensing A,
McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A,
Town A, et al: PDGFRA activating mutations in gastrointestinal
stromal tumors. Science. 299:708–710. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Blanke CD, Demetri GD, von Mehren M,
Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD,
Roberts PJ, Heinz D, et al: Long-term results from a randomized
phase II trial of standard- versus higher-dose imatinib mesylate
for patients with unresectable or metastatic gastrointestinal
stromal tumors expressing KIT. J Clin Oncol. 26:620–625. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yeh CN, Chen YY, Tseng JH, Chen JS, Chen
TW, Tsai CY, Cheng CT, Jan YY and Chen MF: Imatinib mesylate
forpatients with recurrent or metastatic gastrointestinal stromal
tumors expressing KIT: A decade experience from Taiwan. Transl
Oncol. 4:328–335. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Heinrich MC, Corless CL, Blanke CD,
Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M,
Fletcher CD, Sandau K, et al: Molecular correlates of imatinib
resistance in gastrointestinal stromal tumors. J Clin Oncol.
24:4764–4774. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Heinrich MC, Maki RG, Corless CL,
Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB,
Fletcher JA, et al: Primary and secondary kinase genotypes
correlate with the biological and clinical activity of sunitinib in
imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol.
26:5352–5359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Demetri GD, van Oosterom AT, Garrett CR,
Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich
MC, Morgan JA, et al: Efficacy and safety of sunitinib in patients
with advanced gastrointestinal stromal tumour after failure of
imatinib: A randomised controlled trial. Lancet. 368:1329–1338.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Demetri GD, Reichardt P, Kang YK, Blay JY,
Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M,
Joensuu H, et al GRID study investigators: Efficacy and safety of
regorafenib for advanced gastrointestinal stromal tumours after
failure of imatinib and sunitinib (GRID): An international,
multicentre, randomised, placebo-controlled, phase 3 trial. Lancet.
381:295–302. 2013. View Article : Google Scholar
|
|
12
|
Yeh CN, Chen MH, Chen YY, Yang CY, Yen CC,
Tzen CY, Chen LT and Chen JS: A phase II trial of regorafenib in
patients with metastatic and/or a unresectable gastrointestinal
stromal tumor harboring secondary mutations of exon 17. Oncotarget.
8:44121–44130. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bauer S, Yu LK, Demetri GD and Fletcher
JA: Heat shock protein 90 inhibition in imatinib-resistant
gastrointestinal stromal tumor. Cancer Res. 66:9153–9161. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mühlenberg T, Zhang Y, Wagner AJ,
Grabellus F, Bradner J, Taeger G, Lang H, Taguchi T, Schuler M,
Fletcher JA, et al: Inhibitors of deacetylases suppress oncogenic
KIT signaling, acetylate HSP90, and induce apoptosis in
gastrointestinal stromal tumors. Cancer Res. 69:6941–6950. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bauer S, Duensing A, Demetri GD and
Fletcher JA: KIT oncogenic signaling mechanisms in
imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT
is a crucial survival pathway. Oncogene. 26:7560–7568. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pantaleo MA, Nicoletti G, Nanni C, Gnocchi
C, Landuzzi L, Quarta C, Boschi S, Nannini M, Di Battista M,
Castellucci P, et al: Preclinical evaluation of KIT/PDGFRA and mTOR
inhibitors in gastrointestinal stromal tumors using small animal
FDG PET. J Exp Clin Cancer Res. 29:1732010. View Article : Google Scholar
|
|
17
|
Bendell JC, Bauer TM, Lamar R, Joseph M,
Penley W, Thompson DS, Spigel DR, Owera R, Lane CM, Earwood C, et
al: A phase 2 study of the Hsp90 inhibitor AUY922 as treatment for
patients with refractory gastrointestinal stromal tumors. Cancer
Invest. 34:265–270. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Deming DA, Ninan J, Bailey HH, Kolesar JM,
Eickhoff J, Reid JM, Ames MM, McGovern RM, Alberti D, Marnocha R,
et al: A Phase I study of intermittently dosed vorinostat in
combination with bortezomib in patients with advanced solid tumors.
Invest New Drugs. 32:323–329. 2014. View Article : Google Scholar :
|
|
19
|
Schöffski P, Reichardt P, Blay JY, Dumez
H, Morgan JA, Ray-Coquard I, Hollaender N, Jappe A and Demetri GD:
A phase I-II study of everolimus (RAD001) in combination with
imatinib in patients with imatinib-resistant gastrointestinal
stromal tumors. Ann Oncol. 21:1990–1998. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chi P, Chen Y, Zhang L, Guo X, Wongvipat
J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, et al: ETV1 is
a lineage survival factor that cooperates with KIT in
gastrointestinal stromal tumours. Nature. 467:849–853. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ran L, Sirota I, Cao Z, Murphy D, Chen Y,
Shukla S, Xie Y, Kaufmann MC, Gao D, Zhu S, et al: Combined
inhibition of MAP kinase and KIT signaling synergistically
destabilizes ETV1 and suppresses GIST tumor growth. Cancer Discov.
5:304–315. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lamb J, Crawford ED, Peck D, Modell JW,
Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et
al: The Connectivity Map: Using gene-expression signatures to
connect small molecules, genes, and disease. Science.
313:1929–1935. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lamb J: The Connectivity Map: A new tool
for biomedical research. Nat Rev Cancer. 7:54–60. 2007. View Article : Google Scholar
|
|
24
|
Li C and Hung WW: Model-based analysis of
oligonucleotide arrays: model validation, design issues and
standard error application. Genome Biol.
2:RESEARCH00322001.PubMed/NCBI
|
|
25
|
Li C and Wong WH: Model-based analysis of
oligonucleotide arrays: Expression index computation and outlier
detection. Proc Natl Acad Sci USA. 98:31–36. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tuveson DA, Willis NA, Jacks T, Griffin
JD, Singer S, Fletcher CD, Fletcher JA and Demetri GD: STI571
inactivation of the gastrointestinal stromal tumor c-KIT
oncoprotein: Biological and clinical implications. Oncogene.
20:5054–5058. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun X, Hung K, Wu L, Sidransky D and Guo
B: Detection of tumor mutations in the presence of excess amounts
of normal DNA. Nat Biotechnol. 20:186–189. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ross P, Hall L, Smirnov I and Haff L: High
level multiplex genotyping by MALDI-TOF mass spectrometry. Nat
Biotechnol. 16:1347–1351. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: Application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang L, Yu J, Pan H, Hu P, Hao Y, Cai W,
Zhu H, Yu AD, Xie X, Ma D, et al: Small molecule regulators of
autophagy identified by an image-based high-throughput screen. Proc
Natl Acad Sci USA. 104:19023–19028. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen ZH, Kim HP, Sciurba FC, Lee SJ,
Feghali-Bostwick C, Stolz DB, Dhir R, Landreneau RJ, Schuchert MJ,
Yousem SA, et al: Egr-1 regulates autophagy in cigarette
smoke-induced chronic obstructive pulmonary disease. PLoS One.
3:e33162008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guha M, O'Connell MA, Pawlinski R, Hollis
A, McGovern P, Yan SF, Stern D and Mackman N: Lipopolysaccharide
activation of the MEK-ERK1/2 pathway in human monocytic cells
mediates tissue factor and tumor necrosis factor alpha expression
by inducing Elk-1 phosphorylation and Egr-1 expression. Blood.
98:1429–1439. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jang BG, Lee HE and Kim WH: ETV1 mRNA is
specifically expressed in gastrointestinal stromal tumors. Virchows
Arch. 467:393–403. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang SE, Xiang B, Guix M, Olivares MG,
Parker J, Chung CH, Pandiella A and Arteaga CL: Transforming growth
factor beta engages TACE and ErbB3 to activate
phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast
cancer and desen-sitizes cells to trastuzumab. Mol Cell Biol.
28:5605–5620. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hieronymus H, Lamb J, Ross KN, Peng XP,
Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, et al:
Gene expression signature-based chemical genomic prediction
identifies a novel class of HSP90 pathway modulators. Cancer Cell.
10:321–330. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wei G, Twomey D, Lamb J, Schlis K, Agarwal
J, Stam RW, Opferman JT, Sallan SE, den Boer ML, Pieters R, et al:
Gene expression-based chemical genomics identifies rapamycin as a
modulator of MCL1 and glucocorticoid resistance. Cancer Cell.
10:331–342. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Garman KS, Acharya CR, Edelman E, Grade M,
Gaedcke J, Sud S, Barry W, Diehl AM, Provenzale D, Ginsburg GS, et
al: A genomic approach to colon cancer risk stratification yields
biologic insights into therapeutic opportunities. Proc Natl Acad
Sci USA. 105:19432–19437. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Choi JH, Yang YR, Lee SK, Kim SH, Kim YH,
Cha JY, Oh SW, Ha JR, Ryu SH and Suh PG: Potential inhibition of
PDK1/Akt signaling by phenothiazines suppresses cancer cell
proliferation and survival. Ann NY Acad Sci. 1138:393–403. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rho SB, Kim BR and Kang S: A gene
signature-based approach identifies thioridazine as an inhibitor of
phosphati-dylinositol-3′-kinase (PI3K)/AKT pathway in ovarian
cancer cells. Gynecol Oncol. 120:121–127. 2011. View Article : Google Scholar
|
|
41
|
Yeh CT, Wu AT, Chang PM, Chen KY, Yang CN,
Yang SC, Ho CC, Chen CC, Kuo YL, Lee PY, et al: Trifluoperazine, an
antipsychotic agent, inhibits cancer stem cell growth and overcomes
drug resistance of lung cancer. Am J Respir Crit Care Med.
186:1180–1188. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sachlos E, Risueño RM, Laronde S,
Shapovalova Z, Lee JH, Russell J, Malig M, McNicol JD, Fiebig-Comyn
A, Graham M, et al: Identification of drugs including a dopamine
receptor antagonist that selectively target cancer stem cells.
Cell. 149:1284–1297. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Koren J III, Jinwal UK, Jin Y, O'Leary J,
Jones JR, Johnson AG, Blair LJ, Abisambra JF, Chang L, Miyata Y, et
al: Facilitating Akt clearance via manipulation of Hsp70 activity
and levels. J Biol Chem. 285:2498–2505. 2010. View Article : Google Scholar :
|
|
44
|
Polischouk AG, Holgersson A, Zong D,
Stenerlöw B, Karlsson HL, Möller L, Viktorsson K and Lewensohn R:
The antipsychotic drug trifluoperazine inhibits DNA repair and
sensitizes non small cell lung carcinoma cells to DNA double-strand
break induced cell death. Mol Cancer Ther. 6:2303–2309. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu F, Yang X, Geng M and Huang M:
Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer
therapy. Acta Pharm Sin B. 8:552–562. 2018. View Article : Google Scholar : PubMed/NCBI
|
